Literature DB >> 10545594

A direct interaction between EXT proteins and glycosyltransferases is defective in hereditary multiple exostoses.

A D Simmons1, M M Musy, C S Lopes, L Y Hwang, Y P Yang, M Lovett.   

Abstract

Hereditary multiple exostoses (HME) is an autosomal dominant condition in which bony outgrowths occur from the juxtaepiphyseal regions of the long bones. In a few percent of cases these exostoses undergo malignant transformation to chondrosarcomas. HME results from mutations in one of two homologous genes, EXT1 and EXT2. These are members of a new gene family that is conserved from Caenorhabditis elegans to higher vertebrates. In humans this family comprises five genes which are most conserved at their C-termini, but they do not contain any discernible functional motifs and their function(s) is unclear. Indirect evidence suggests that EXT proteins are involved in glycosaminoglycan synthesis, act as tumor suppressors and affect hedgehog signaling. One recent study has also reported that these proteins co-purify with glycosyltransferase (GlcA and GlcNAc transferase) activity and on that basis it has been postulated that they are themselves glycosyl-transferases. We performed two-hybrid screens with a fragment of EXT2 from the region that is most highly conserved in the gene family and identified two interacting proteins: the tumor necrosis factor type 1 associated protein and a novel UDP-GalNAc:poly-peptide N -acetylgalactosaminyltransferase. Significantly, both these interactions were abrogated by a disease-causing EXT mutation, indicating that they are important in the etiology of HME. The EXT2-GalNAc-T5 interaction provides the first direct physical link between EXT proteins and known components of glycosamino-glycan synthesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545594     DOI: 10.1093/hmg/8.12.2155

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  22 in total

1.  The EXT1/EXT2 tumor suppressors: catalytic activities and role in heparan sulfate biosynthesis.

Authors:  C Senay; T Lind; K Muguruma; Y Tone; H Kitagawa; K Sugahara; K Lidholt; U Lindahl; M Kusche-Gullberg
Journal:  EMBO Rep       Date:  2000-09       Impact factor: 8.807

Review 2.  The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins.

Authors:  G Duncan; C McCormick; F Tufaro
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 3.  Organization of Golgi glycosyltransferases in membranes: complexity via complexes.

Authors:  W W Young
Journal:  J Membr Biol       Date:  2004-03-01       Impact factor: 1.843

4.  Pancreatic reg I binds MKP-1 and regulates cyclin D in pancreatic-derived cells.

Authors:  Cathy M Mueller; Hong Zhang; Michael E Zenilman
Journal:  J Surg Res       Date:  2008-04-28       Impact factor: 2.192

Review 5.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

6.  Emerging paradigms for the initiation of mucin-type protein O-glycosylation by the polypeptide GalNAc transferase family of glycosyltransferases.

Authors:  Thomas A Gerken; Oliver Jamison; Cynthia L Perrine; Jeremy C Collette; Helen Moinova; Lakshmeswari Ravi; Sanford D Markowitz; Wei Shen; Himatkumar Patel; Lawrence A Tabak
Journal:  J Biol Chem       Date:  2011-02-24       Impact factor: 5.157

7.  No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas.

Authors:  Christianne M A Reijnders; Cathelijn J F Waaijer; Andrew Hamilton; Emilie P Buddingh; Sander P D Dijkstra; John Ham; Egbert Bakker; Karoly Szuhai; Marcel Karperien; Pancras C W Hogendoorn; Sally E Stringer; Judith V M G Bovée
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

8.  The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting.

Authors:  Liesbeth Hameetman; Petra Kok; Paul H C Eilers; Anne-Marie Cleton-Jansen; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2005-03-03       Impact factor: 4.064

9.  Mucin-type O-glycosylation is controlled by short- and long-range glycopeptide substrate recognition that varies among members of the polypeptide GalNAc transferase family.

Authors:  Leslie Revoredo; Shengjun Wang; Eric Paul Bennett; Henrik Clausen; Kelley W Moremen; Donald L Jarvis; Kelly G Ten Hagen; Lawrence A Tabak; Thomas A Gerken
Journal:  Glycobiology       Date:  2015-11-26       Impact factor: 4.313

10.  The lectin domain of the polypeptide GalNAc transferase family of glycosyltransferases (ppGalNAc Ts) acts as a switch directing glycopeptide substrate glycosylation in an N- or C-terminal direction, further controlling mucin type O-glycosylation.

Authors:  Thomas A Gerken; Leslie Revoredo; Joseph J C Thome; Lawrence A Tabak; Malene Bech Vester-Christensen; Henrik Clausen; Gagandeep K Gahlay; Donald L Jarvis; Roy W Johnson; Heather A Moniz; Kelley Moremen
Journal:  J Biol Chem       Date:  2013-05-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.